

monoclonal antibody comprises a human antibody.

10. (Amended) The method of claim 6 wherein said agonistic anti-DR5 receptor antibody is an antibody which cross-reacts with more than one Apo-2 ligand receptor.

11. (Amended) The method of claim 6 further comprising exposing the cancer cells to one or more growth inhibitory agents.

12. (Amended) The method of claim 6 further comprising exposing the cells to radiation.

13. (Amended) The method of claim 6 wherein the cancer cells comprise colorectal cancer cells.

19. (Amended) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to agonistic anti-DR5 receptor antibody and CPT-11 in an amount effective to synergistically induce apoptosis in said mammalian cancer cells, wherein said agonistic anti-DR5 receptor antibody is a monoclonal antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor.

20. (As filed) The method of claim 19 wherein said mammalian cancer cells are exposed to said antibody and CPT-11 *in vitro*.

21. (As filed) The method of claim 19 wherein said mammalian cancer cells are exposed to said antibody and CPT-11 *in vivo*.

22. (As filed) The method of claim 19 wherein said agonistic anti-DR5 receptor antibody is a chimeric antibody.

23. (As filed) The method of claim 22 wherein said chimeric antibody includes a variable or hypervariable domain of the anti-DR5 monoclonal antibody secreted by the hybridoma deposited as

ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534.

24. (As filed) The method of claim 19 wherein said agonistic anti-DR5 antibody binds to the same DR5 receptor epitope to which the anti-DR5 monoclonal secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534 binds.

25. (As filed) The method of claim 19 wherein said agonistic anti-DR5 antibody is a human antibody.

26. (As filed) The method of claim 19 wherein said agonistic anti-DR5 antibody specifically binds to DR5 receptor.

27. (As filed) The method of claim 26 wherein said antibody has a DR5 receptor binding affinity of 10^8 M^{-1} to 10^{12} M^{-1} .

28. (As filed) The method of claim 19 wherein said agonistic anti-DR5 receptor antibody inhibits binding of Apo-2 ligand to DR5 receptor.

29. (As filed) The method of claim 19 wherein said agonistic anti-DR5 receptor antibody is a cross-reactive antibody which binds DR5 receptor and one or more other Apo-2 ligand receptors.

30. (As filed) The method of claim 19 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and *E. coli*.

31. (As filed) The method of claim 19 wherein said mammalian cancer cells are colon cancer cells or colorectal cancer cells.

32. (Amended) A method of inducing apoptosis in mammalian colon or colorectal cancer cells comprising exposing mammalian colon or

colorectal cancer cells to agonistic anti-DR5 receptor antibody and CPT-11 in an amount effective to synergistically induce apoptosis in said mammalian cancer cells, wherein said agonistic anti-DR5 receptor antibody is a monoclonal antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor.

33. (As filed) The method of claim 32 wherein said agonistic anti-DR5 receptor antibody is a chimeric antibody.

34. (As filed) The method of claim 33 wherein said chimeric antibody includes a variable or hypervariable domain of the anti-DR5 monoclonal antibody secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534.

35. (As filed) The method of claim 32 wherein said agonistic anti-DR5 antibody binds to the same DR5 receptor epitope to which the anti-DR5 monoclonal secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534 binds.

36. (As filed) The method of claim 32 wherein said agonistic anti-DR5 antibody is a human antibody.

37. (As filed) The method of claim 32 wherein said agonistic anti-DR5 antibody specifically binds to DR5 receptor.

38. (As filed) The method of claim 37 wherein said antibody has a DR5 receptor binding affinity of 10^8 M^{-1} to 10^{12} M^{-1} .

39. (As filed) The method of claim 32 wherein said agonistic anti-DR5 receptor antibody inhibits binding of Apo-2 ligand to DR5 receptor.

40. (As filed) The method of claim 32 wherein said agonistic anti-

DR5 receptor antibody is a cross-reactive antibody which binds DR5 receptor and one or more other Apo-2 ligand receptors.

41. (As filed) The method of claim 19 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and *E. coli*.

42. (Amended) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to agonistic anti-DR5 receptor antibody and CPT-11 in an amount effective to synergistically induce apoptosis in said mammalian cancer cells, wherein said agonistic anti-DR5 receptor antibody is a monoclonal antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor and binds to the same DR5 receptor epitope to which the anti-DR5 monoclonal secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534 binds.

43. (Amended) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to agonistic anti-DR5 receptor antibody and CPT-11 in an amount effective to synergistically induce apoptosis in said mammalian cancer cells, wherein said agonistic anti-DR5 receptor antibody is a chimeric antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor and includes a variable or hypervariable domain of the anti-DR5 monoclonal antibody secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534. ---